161 related articles for article (PubMed ID: 18786813)
1. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.
Kwon JS; Kim E; Kang DH; Choi JS; Yu KS; Jang IJ; Shin SG;
Eur Neuropsychopharmacol; 2008 Dec; 18(12):897-907. PubMed ID: 18786813
[TBL] [Abstract][Full Text] [Related]
2. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
Miura I; Takeuchi S; Katsumi A; Mori A; Kanno K; Yang Q; Mashiko H; Numata Y; Niwa S
J Clin Psychopharmacol; 2012 Feb; 32(1):106-9. PubMed ID: 22198450
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
[TBL] [Abstract][Full Text] [Related]
4. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.
Shen YC; Chen SF; Chen CH; Lin CC; Chen SJ; Chen YJ; Luu SU
J Psychiatr Res; 2009 Mar; 43(6):600-6. PubMed ID: 18926547
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
6. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
[TBL] [Abstract][Full Text] [Related]
7. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.
Nagai G; Mihara K; Nakamura A; Suzuki T; Nemoto K; Kagawa S; Ohta I; Arakaki H; Kondo T
Psychiatry Clin Neurosci; 2012 Oct; 66(6):518-24. PubMed ID: 23066770
[TBL] [Abstract][Full Text] [Related]
8. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors.
Chen SF; Shen YC; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):470-4. PubMed ID: 19302829
[TBL] [Abstract][Full Text] [Related]
9. Taq1A polymorphism in the dopamine D2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteers.
Kim E; Kwon JS; Shin YW; Lee JS; Kang WJ; Jo HJ; Lee JM; Yu KS; Kang DH; Cho JY; Jang IJ; Shin SG
Pharmacogenet Genomics; 2008 Feb; 18(2):91-7. PubMed ID: 18192895
[TBL] [Abstract][Full Text] [Related]
10. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Lin CH; Lin SH; Jang FL
J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
[TBL] [Abstract][Full Text] [Related]
12. No influence of FAT polymorphisms in response to aripiprazole.
Pae CU; Chiesa A; Mandelli L; De Ronchi D; Serretti A
J Hum Genet; 2010 Jan; 55(1):32-6. PubMed ID: 19893579
[TBL] [Abstract][Full Text] [Related]
13. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
[TBL] [Abstract][Full Text] [Related]
14. Trial of aripiprazole in the treatment of first-episode schizophrenia.
Lee HY; Ham BJ; Kang RH; Paik JW; Hahn SW; Lee MS; Lee MS
Psychiatry Clin Neurosci; 2010 Feb; 64(1):38-43. PubMed ID: 20416024
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
[TBL] [Abstract][Full Text] [Related]
16. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
Zhao T; Park TW; Yang JC; Huang GB; Kim MG; Lee KH; Chung YC
Int Clin Psychopharmacol; 2012 Jul; 27(4):184-90. PubMed ID: 22426471
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
Mitsonis CI; Dimopoulos NP; Mitropoulos PA; Kararizou EG; Katsa AN; Tsakiris FE; Katsanou MN
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):373-7. PubMed ID: 17092620
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
Zimbroff D; Warrington L; Loebel A; Yang R; Siu C
Int Clin Psychopharmacol; 2007 Nov; 22(6):363-70. PubMed ID: 17917555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
